SG11201811768WA - Modulation of tjp1 expression to regulate regeneration of heart cells - Google Patents
Modulation of tjp1 expression to regulate regeneration of heart cellsInfo
- Publication number
- SG11201811768WA SG11201811768WA SG11201811768WA SG11201811768WA SG11201811768WA SG 11201811768W A SG11201811768W A SG 11201811768WA SG 11201811768W A SG11201811768W A SG 11201811768WA SG 11201811768W A SG11201811768W A SG 11201811768WA SG 11201811768W A SG11201811768W A SG 11201811768WA
- Authority
- SG
- Singapore
- Prior art keywords
- singapore
- inhibitor
- tjpl
- international
- institute
- Prior art date
Links
- 210000002064 heart cell Anatomy 0.000 title abstract 2
- 230000008929 regeneration Effects 0.000 title abstract 2
- 238000011069 regeneration method Methods 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 abstract 7
- 108091027967 Small hairpin RNA Proteins 0.000 abstract 3
- 210000004027 cell Anatomy 0.000 abstract 3
- 239000004055 small Interfering RNA Substances 0.000 abstract 3
- 241000702421 Dependoparvovirus Species 0.000 abstract 2
- 102000048238 Neuregulin-1 Human genes 0.000 abstract 2
- 108090000556 Neuregulin-1 Proteins 0.000 abstract 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 abstract 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 abstract 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 abstract 2
- 206010000891 acute myocardial infarction Diseases 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 208000019622 heart disease Diseases 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 239000011148 porous material Substances 0.000 abstract 2
- 102100029378 Follistatin-related protein 1 Human genes 0.000 abstract 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 abstract 1
- 101001062535 Homo sapiens Follistatin-related protein 1 Proteins 0.000 abstract 1
- 101000802356 Homo sapiens Tight junction protein ZO-1 Proteins 0.000 abstract 1
- 101100069392 Mus musculus Gzma gene Proteins 0.000 abstract 1
- 108020004459 Small interfering RNA Proteins 0.000 abstract 1
- 102100034686 Tight junction protein ZO-1 Human genes 0.000 abstract 1
- 210000004413 cardiac myocyte Anatomy 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 230000002526 effect on cardiovascular system Effects 0.000 abstract 1
- 210000002950 fibroblast Anatomy 0.000 abstract 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
- 238000001356 surgical procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/761—Adenovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1858—Platelet-derived growth factor [PDGF]
- A61K38/1866—Vascular endothelial growth factor [VEGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1883—Neuregulins, e.g.. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1808—Epidermal growth factor [EGF] urogastrone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1841—Transforming growth factor [TGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
- C12N2310/122—Hairpin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/531—Stem-loop; Hairpin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Vascular Medicine (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Cardiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Virology (AREA)
- Mycology (AREA)
- Marine Sciences & Fisheries (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property MD 1101111 0 DOI HIM 011101 0 011111111111111111111111111111111111111111111111 Organization International Bureau (10) International Publication Number (43) International Publication Date ......0\"\"1 WO 2018/052374 Al 22 March 2018 (22.03.2018) W I PO I PC T (51) International Patent Classification: (72) Inventors: HUNZIKER, Walter; c/o Institute of Molec- A61K 31/713 (2006.01) A61P 9/10 (2006.01) ular and Cell Biology, 61 Biopolis Drive, Proteos, Singa- C12N 15/113 (2010.01) pore 138673 (SG). XU, Jianliang; c/o Institute of Molecu- (21) International Application Number: lar and Cell Biology, 61 Biopolis Drive, Proteos, Singapore PCT/SG2017/050462 138673 (SG). WANG, Jiong-Wei; Department of Surgery and Cardiovascular Research Institute (CVRI), NUS, Singa- (22) International Filing Date: pore, Centre for Translational Medicine, MD6, #08-01, 14 14 September 2017 (14.09.2017) Medical Drive, Singapore 117599 (SG). KAUSALYA, P. Jaya; c/o Institute of Molecular and Cell Biology, 61 Biopo- (25) Filing Language: English lis Drive, Proteos, Singapore 138673 (SG). (26) Publication Language: English (74) Agent: SPRUSON & FERGUSON (ASIA) PTE LTD; (30) Priority Data: P.O. Box 1531, Robinson Road Post Office, Singapore 10201607673U 14 September 2016 (14.09.2016) SG 903031 (SG). (71) Applicants: AGENCY FOR SCIENCE, TECHNOLO- (81) Designated States (unless otherwise indicated, for every — GY AND RESEARCH [SG/SG]; 1 Fusionopolis Way, kind of national protection available): AE, AG, AL, AM, #20-10 Connexis North Tower, Singapore 138632 (SG). AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, NATIONAL UNIVERSITY OF SINGAPORE [SG/SG]; CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, 21 Lower Kent Ridge Road, Singapore 119077 (SG). DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, = Title: MODULATION OF TJP1 EXPRESSION TO REGULATE REGENERATION OF HEART CELLS (54) A = = 0 ZO-1 , GAPDH — = = = B = mTJP1 shRNA#1 --- SEQ ID NO: 3 CCGGCGTGGATTGAACTTACTAAATCTCGAGATTTAGTAAGTTCAATCCACGTTTITG = = mTSP1 shRNA#2 --- SEQ ID NO: 4 = — CCGGCCGCGAAGTTATGAGCAAGTTCTCGAGAACTTGCTCATAACTTCGCGGTTITTG = Figure 8 — ,-, 71' (57) : The invention is a method for treating a heart disease, in particular acute myocardial infarction (AMI) in a subject com- IN en prising the step of administering to the subject a Tjpl inhibitor, wherein administration of said Tjpl inhibitor promotes cardiomyocyte N proliferation. The invention further includes use of Tjpl inhibitor in the manufacture of a medicament for a heart disease, a patch, and In a nucleic acid encoding a Tjpl inhibitor. In a particular embodiment, the Tjpl inhibitor is a nucleic acid, i.e. an siRNA or shRNA of 0 ---, Tjp 1. The invention also includes administration of said Tjpl inhibitor in combination with Neuregulin-1 (NRG1 ), Fibroblast growth '1-1 a'C factor (FGF), Vascular endothelial growth factor (VEGF) or Follistatin-like 1 (Fst 1 ) and wherein said inhibitor is delivered in an C adeno-associated virus of serotype 9 (AAV 9). ei O [Continued on next page] WO 2018/052374 Al 11111111111111111110101011111 O11111O 111111111111111111111111111111111111111111 HOED MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: — of inventorship (Rule 4.17(iv)) Published: — with international search report (Art. 21(3)) — with sequence listing part of description (Rule 5.2(a))
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SG10201607673U | 2016-09-14 | ||
PCT/SG2017/050462 WO2018052374A1 (en) | 2016-09-14 | 2017-09-14 | Modulation of tjp1 expression to regulate regeneration of heart cells |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201811768WA true SG11201811768WA (en) | 2019-01-30 |
Family
ID=61619661
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201811768WA SG11201811768WA (en) | 2016-09-14 | 2017-09-14 | Modulation of tjp1 expression to regulate regeneration of heart cells |
Country Status (5)
Country | Link |
---|---|
US (1) | US11820981B2 (en) |
EP (1) | EP3512528A4 (en) |
CN (2) | CN117357552A (en) |
SG (1) | SG11201811768WA (en) |
WO (1) | WO2018052374A1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111407881A (en) * | 2019-01-07 | 2020-07-14 | 上海泽生科技开发股份有限公司 | Methods and compositions for neuregulin to prevent, treat or delay myocardial damage |
CN113069548B (en) * | 2021-04-23 | 2022-08-02 | 青岛市中医医院(青岛市海慈医院、青岛市康复医学研究所) | Reagent for cardiac revascularization |
WO2023043375A2 (en) * | 2021-09-16 | 2023-03-23 | Agency For Science, Technology And Research | Modulation of tjp1 expression to treat liver diseases |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1333231A (en) * | 2000-07-07 | 2002-01-30 | 上海博德基因开发有限公司 | Novel polypeptide--tight junction protein Z0-1-10.01 and polynucleotide for encoding said polypeptide |
EP1631306A4 (en) * | 2003-05-19 | 2009-08-12 | Univ Columbia | Compositions and methods for treating and preventing heart tissue degeneration, and uses thereof |
WO2011011388A2 (en) * | 2009-07-22 | 2011-01-27 | Children's Medical Center Corporation | Neuregulin induced regeneraton of heart muscle muscle |
WO2013148736A1 (en) | 2012-03-27 | 2013-10-03 | Coda Therapeutics, Inc. | Compositions and treatments based on cadherin modulation |
CN107109410B (en) * | 2014-08-22 | 2021-11-02 | 奥克兰联合服务有限公司 | Channel modulators |
-
2017
- 2017-09-14 CN CN202311295933.3A patent/CN117357552A/en active Pending
- 2017-09-14 SG SG11201811768WA patent/SG11201811768WA/en unknown
- 2017-09-14 US US16/333,586 patent/US11820981B2/en active Active
- 2017-09-14 CN CN201780053180.1A patent/CN110167564B/en active Active
- 2017-09-14 EP EP17851187.9A patent/EP3512528A4/en active Pending
- 2017-09-14 WO PCT/SG2017/050462 patent/WO2018052374A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
CN110167564B (en) | 2023-10-17 |
WO2018052374A1 (en) | 2018-03-22 |
EP3512528A4 (en) | 2020-05-13 |
CN110167564A (en) | 2019-08-23 |
US11820981B2 (en) | 2023-11-21 |
EP3512528A1 (en) | 2019-07-24 |
US20190256846A1 (en) | 2019-08-22 |
CN117357552A (en) | 2024-01-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201809912UA (en) | Hybrid carriers for nucleic acid cargo | |
SG11201806340YA (en) | Zika virus vaccine | |
SG11201906297QA (en) | Nucleic acids encoding crispr-associated proteins and uses thereof | |
SG11201907846VA (en) | Therapeutic rna | |
SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
SG11201810162PA (en) | Polynucleotides encoding citrin for the treatment of citrullinemia type 2 | |
SG11201805120YA (en) | Zika virus vaccine | |
SG11201805570WA (en) | Systems and methods for long term transdermal administration | |
SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
SG11201909963YA (en) | Methods for treating dravet syndrome | |
SG11201407486PA (en) | Compositions and methods for modulating utrn expression | |
SG11201805828YA (en) | Method of treating c3 glomerulopathy | |
SG11201908060PA (en) | Wound healing medicament | |
SG11201904535VA (en) | Prevention and treatment of bone and cartilage damage or disease | |
SG11201907934YA (en) | Devices, methods, and compositions useful in cryo-preservation, -storage, -transport, and application of therapeutic mammalian cells | |
SG11201907583TA (en) | Methods for treating complement-mediated diseases and disorders | |
SG11201901063SA (en) | Therapeutic agents for neurodegenerative diseases | |
SG11201901048VA (en) | Pharmaceutical compositions and uses directed to lysosomal storage disorders | |
SG11201900361RA (en) | Methods of treating prostate cancer | |
SG11201808221QA (en) | 1,5-dihydro-4h-pyrazolo[3,4-d]pyrimidin-4-ones and 1,5-dihydro-4h-pyrazolo[4,3-c]pyridin-4-ones as pde1 inhibitors | |
SG11201805771XA (en) | Systems and methods for preparation of platelets | |
SG11201811768WA (en) | Modulation of tjp1 expression to regulate regeneration of heart cells | |
SG11201808964PA (en) | Antisense oligomers and methods of using the same for treating diseases associated with the acid alpha-glucosidase gene | |
SG11201900408RA (en) | Topical formulation for promoting wound healing | |
SG11201903770UA (en) | Combination treatments comprising imidazopyrazinones for the treatment of psychiatric and/or cognitive disorders |